1 / 10

PR asugrel IN Comparison to C lopidogrel for I nhibition of PL atelet Activation and Aggr E gation (PRINCIPLE) – T

PR asugrel IN Comparison to C lopidogrel for I nhibition of PL atelet Activation and Aggr E gation (PRINCIPLE) – TIMI 44. Study Design. Loading Phase N=201 . Clopidogrel naïve No planned GP IIb/IIIa use. Planned Elective PCI Baseline Laboratory Measures. Clopidogrel 600 mg.

jag
Download Presentation

PR asugrel IN Comparison to C lopidogrel for I nhibition of PL atelet Activation and Aggr E gation (PRINCIPLE) – T

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PRasugrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation (PRINCIPLE) – TIMI 44

  2. Study Design Loading Phase N=201 Clopidogrel naïve No planned GP IIb/IIIa use Planned Elective PCI Baseline Laboratory Measures Clopidogrel 600 mg Prasugrel 60 mg 0.5 h Post-Loading Dose Labs Coronary Angiography Post-Angiography Labs PCI No PCI Maintenance Phase N=100 6h* Labs, 18-24h Labs 6h* Labs, 15d Events Clopidogrel 150 mg x 14d Prasugrel 10 mg x 14d 15d Clinical Events, Labs,† CROSSOVER Prasugrel 10 mg x 14d Clopidogrel 150 mg x 14d 29d Clinical Events, Labs† 1º EPs: *Loading = 6h IPA (20 µM ADP); †Maintenance = 15d or 29d IPA (20 µM ADP) Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association

  3. PRIMARY EP Acute Phase: IPA 20 uM ADP P<0.0001 for each Prasugrel 60 mg IPA (%; 20 mM ADP) Hours Wiviott SD et al, Circulation 2007 Copyright ©2007 American Heart Association

  4. Maximal Platelet Aggregation (MPA) P<0.0001 for each MPA (%; 20 mM ADP) Prasugrel 60 mg Hours

  5. VASP Phosphorylation Ratio P<0.0001 for each VASP Phosphorylation Ratio Prasugrel 60 mg Hours

  6. PRIMARY EP Chronic Phase: IPA 20 uM ADP Difference Between Treatments: 14.9 [95% CI 10.6 – 19.3], P<0.0001 Prasugrel 10 mg Prasugrel 10 mg IPA (%; 20 mM ADP) Days

  7. Maximal Platelet Aggregation (MPA) Difference Between Treatments: 11.3 [95% CI 8.1 – 14.5], P<0.0001 Clopidogrel 150 mg Clopidogrel 150 mg MPA (%; 20 mM ADP) Prasugrel 10 mg Prasugrel 10 mg Days

  8. VASP Phosphorylation Ratio Difference Between Treatments: 20.1 [95% CI 14.5 – 25.7], P<0.0001 Clopidogrel 150 mg Clopidogrel 150 mg VASP Phosphorylation Ratio Prasugrel 10 mg Prasugrel 10 mg Days

  9. Thienopyridine Hyporesponsiveness: IPA 20 uM ADP < 20% P =0.0008 Clopidogrel Prasugrel P <0.0001 Percent of Subjects P =0.0005 P =0.0002 P =0.06 P =0.18 Hours

  10. Implications PRINCIPLE – TIMI 44 extends the pharmacologic superiority of the TRITON – TIMI 38 dose of prasugrel (60 mg/10 mg) to higher doses of clopidogrel (600 mg/150mg) in PCI. TRITON – TIMI 381tested hypothesis that an agent that with higher and more consistent IPA than standard approved clopidogrel (300 mg/ 75 mg) will improve clinical outcomes 1 Wiviott SD, Braunwald E, McCabe CH et al NEJM2007

More Related